#PLHCV - Twitter Hashtag

about 5 years ago

TQ for your contribution ☺️. Like you, I am also proud to be part of this effort as the country principal investigator of the STORM-C trial. Outcome of our work led to the registration of #Ravidasvir in 🇲🇾. We can now treat more #PLHCV. @MSGastroHepato @unimalaya

Wah Kheong @WahKheong

about 5 years ago

Proud to have been part of this effort to make affordable treatment a reality for people living with chronic hepatitis C infection. @drsstan @MSGastroHepato @unimalaya https://t.co/FGZ4oGe1rl

0

10

3

0

1

12

6

0

Soek-Siam Tan @drsstan

about 5 years ago

@JMP_DNDi @DGHisham @yasserfayed7 @kamarulbahrin @radzi_dr @YokeLing15 @YusofAkhmal Definitely. Modelling showed we need to treat about 20K #PLHCV annually for #HCV elimination. Managing HCV in this pandemic made me wishing for the simple Ravidasvir+sofosbuvir regimen. Now approved, large scale-up with this proven regimen should be the focus.

0

7

3

0

Soek-Siam Tan @drsstan

about 5 years ago

@Ilham03013425 @Abraham60373150 Thank you. Yes, lets find #PLHCV and link to Ravidasvir + sofosbuvir therapy.

0

2

0

Soek-Siam Tan @drsstan

about 5 years ago

Humbled to be able part of this project. Started 6 years ago with the target profile for a compound we need for #PLHCV and the healthcare facilities in Malaysia 🇲🇾. Now I look forward to be able to prescribe this very efficacious regimen.

Clinical Research MY

@ClinicalRsrchMY

about 5 years ago

What started as a collaborative trial between DNDi, CRM and ICR has now led to Malaysia being a step closer in its plan to eradicate Hep B & C! Great work by the study team! @ICR_NIH @JMP_DNDi @DNDi @DGHisham @radzi_dr @drsstan

0

57

19

0

12

4

0

Soek-Siam Tan @drsstan

about 5 years ago

TQ for accepting our work. I am honoured to study #ravidasvir + sofosbuvir treatment with my patients in mind and co-first author. A ribavirin free regimen with 96% SVR even in #HCV GT3 with cirrhosis. TQ to #PLHCV who participated, @DNDi @KKMPutrajaya @ICR_NIH @ClinicalRsrchMY

The Lancet Gastroenterology & Hepatology @LancetGastroHep

about 5 years ago

New research - Andrieux-Meyer et al - Efficacy & safety of ravidasvir + sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1) @DNDi #hepC #HCV #nohep #endhep @Hep_Alliance @MedsPatentPool #livertwitter